How GLP-1 Drugs and SGLT2 Inhibitors Are Reshaping Treatment for Heart, Kidney, and Metabolic Disease
SGLT2 inhibitors and GLP-1 receptor agonists have become guideline-endorsed cornerstones for treating the interconnected triad of cardiovascular disease, chronic kidney disease, and metabolic conditions.
Quick Facts
What This Study Found
SGLT2 inhibitors and GLP-1 receptor agonists have strong, complementary evidence for cardiovascular and kidney protection in CKM syndrome and are now widely guideline-endorsed.
Key Numbers
Review covers the expansion of CKM treatments over the past decade, including evidence from major cardiovascular and renal outcome trials.
How They Did This
Narrative review comparing clinical trial evidence for established and emerging CKM syndrome therapies, with focus on SGLT2 inhibitors, GLP-1 RAs, and pipeline drug classes.
Why This Research Matters
Heart disease, kidney disease, diabetes, and obesity frequently coexist and worsen each other. Having two proven drug classes that protect multiple organs simultaneously — rather than treating each condition in isolation — represents a paradigm shift in how these interconnected diseases are managed.
The Bigger Picture
The concept of CKM syndrome reflects a shift from siloed treatment of individual diseases to integrated management of interconnected metabolic and organ damage. GLP-1 receptor agonists and SGLT2 inhibitors are at the center of this shift, with dual and triple agonists in the pipeline promising even broader protection.
What This Study Doesn't Tell Us
As a narrative review, this does not include new primary data or systematic methodology. Real-world prescribing patterns often lag behind guideline recommendations. The review acknowledges that the growing complexity of available therapies makes clinical decision-making increasingly challenging.
Questions This Raises
- ?Should GLP-1 agonists and SGLT2 inhibitors be routinely combined for CKM patients, and in what order?
- ?Will emerging dual GLP-1/GIP agonists like tirzepatide further improve cardiovascular and renal outcomes?
- ?How can real-world prescribing better reflect the strong evidence supporting these therapies?
Trust & Context
- Key Stat:
- Guideline-endorsed Both SGLT2 inhibitors and GLP-1 receptor agonists are now widely recommended in clinical guidelines for their cardiovascular and kidney protective benefits in CKM syndrome.
- Evidence Grade:
- This is a narrative review synthesizing evidence from multiple large randomized controlled trials. The underlying evidence is strong, though the review itself does not generate new data.
- Study Age:
- Published in 2025, reflecting the most current guideline recommendations and pipeline therapies.
- Original Title:
- Established and Emerging Therapies for Cardiovascular-Kidney-Metabolic Syndrome: Harnessing the Benefits of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and Beyond.
- Published In:
- Heart, lung & circulation, 34(10), 995-1005 (2025)
- Authors:
- Allahwala, Momina A, Marathe, Chinmay S(2), Nelson, Adam J(3), Psaltis, Peter J, Marathe, Jessica A
- Database ID:
- RPEP-09872
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What is CKM syndrome?
Cardiovascular-kidney-metabolic syndrome describes the interconnected cycle where heart disease, kidney disease, diabetes, and obesity worsen each other. It reflects a shift toward treating these conditions as a linked system rather than separate diseases.
Can GLP-1 drugs and SGLT2 inhibitors be taken together?
Yes, and this review suggests their mechanisms are complementary. GLP-1 agonists work primarily through appetite, glucose, and inflammation pathways while SGLT2 inhibitors act on kidney glucose handling and fluid balance. Combining them may offer broader protection.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09872APA
Allahwala, Momina A; Marathe, Chinmay S; Nelson, Adam J; Psaltis, Peter J; Marathe, Jessica A. (2025). Established and Emerging Therapies for Cardiovascular-Kidney-Metabolic Syndrome: Harnessing the Benefits of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and Beyond.. Heart, lung & circulation, 34(10), 995-1005. https://doi.org/10.1016/j.hlc.2025.07.005
MLA
Allahwala, Momina A, et al. "Established and Emerging Therapies for Cardiovascular-Kidney-Metabolic Syndrome: Harnessing the Benefits of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and Beyond.." Heart, 2025. https://doi.org/10.1016/j.hlc.2025.07.005
RethinkPeptides
RethinkPeptides Research Database. "Established and Emerging Therapies for Cardiovascular-Kidney..." RPEP-09872. Retrieved from https://rethinkpeptides.com/research/allahwala-2025-established-and-emerging-therapies
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.